Morgan Stanley Issues Pessimistic Forecast for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price

Y-mAbs Therapeutics (NASDAQ:YMAB) had its price target decreased by investment analysts at Morgan Stanley from $11.00 to $7.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has an “underweight” rating on the stock. Morgan Stanley’s price objective points to a potential upside of 33.33% from the stock’s previous close.

YMAB has been the topic of a number of other reports. Wedbush reaffirmed an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday. HC Wainwright restated a “buy” rating and issued a $22.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday, January 13th. Brookline Capital Management started coverage on shares of Y-mAbs Therapeutics in a research note on Thursday, December 5th. They issued a “buy” rating and a $17.00 price objective on the stock. Finally, Oppenheimer assumed coverage on shares of Y-mAbs Therapeutics in a research note on Monday, November 18th. They set an “outperform” rating and a $23.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $19.30.

Y-mAbs Therapeutics Price Performance

YMAB opened at $5.25 on Wednesday. Y-mAbs Therapeutics has a fifty-two week low of $4.25 and a fifty-two week high of $18.17. The company’s 50 day moving average price is $6.39 and its two-hundred day moving average price is $10.58. The firm has a market capitalization of $235.14 million, a price-to-earnings ratio of -9.72 and a beta of 0.65.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The business had revenue of $26.50 million during the quarter, compared to the consensus estimate of $26.70 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period in the prior year, the firm earned ($0.02) EPS. As a group, equities research analysts predict that Y-mAbs Therapeutics will post -0.65 EPS for the current year.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Acorn Capital Advisors LLC bought a new stake in Y-mAbs Therapeutics in the 4th quarter valued at about $22,408,000. Caligan Partners LP grew its stake in Y-mAbs Therapeutics by 105.3% in the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock valued at $15,718,000 after acquiring an additional 613,175 shares during the period. State Street Corp increased its holdings in shares of Y-mAbs Therapeutics by 50.4% during the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock valued at $15,909,000 after acquiring an additional 405,169 shares in the last quarter. Infinitum Asset Management LLC acquired a new position in shares of Y-mAbs Therapeutics during the fourth quarter worth approximately $1,218,000. Finally, Paradigm Biocapital Advisors LP lifted its holdings in shares of Y-mAbs Therapeutics by 3.7% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,236,346 shares of the company’s stock worth $33,171,000 after purchasing an additional 150,000 shares in the last quarter. Institutional investors and hedge funds own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.